VolitionRx Limited (VNRX)
Market Cap | 52.24M |
Revenue (ttm) | 797,029 |
Net Income (ttm) | -34.91M |
Shares Out | 82.93M |
EPS (ttm) | -0.46 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 52,604 |
Open | 0.625 |
Previous Close | 0.619 |
Day's Range | 0.611 - 0.655 |
52-Week Range | 0.550 - 1.550 |
Beta | 1.17 |
Analysts | Strong Buy |
Price Target | 2.83 (+349.21%) |
Earnings Date | Aug 12, 2024 |
About VNRX
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer det... [Read more]
Financial Performance
In 2023, VolitionRx's revenue was $775,302, an increase of 153.04% compared to the previous year's $306,392. Losses were -$35.32 million, 16.7% more than in 2022.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for VNRX stock is "Strong Buy." The 12-month stock price forecast is $2.83, which is an increase of 349.21% from the latest price.
News
![](https://cdn.snapi.dev/images/v1/o/a/press9-2499565.jpg)
VolitionRx Limited Issues Mid-Year Review Ahead of 2024 Annual Meeting
HENDERSON, Nev. , June 27, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has issued a mid-year review to stockholders, ahead of its ...
![](https://cdn.snapi.dev/images/v1/d/t/press8-2480082.jpg)
Nexalin Technology and VolitionRX Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / ACCESSWIRE / June 14, 2024 / RedChip Companies will air interviews with Nexalin Technology, Inc. (Nasdaq:NXL) ("Nexalin") and VolitionRX Limited (NYSE American:VNRX) ("Volition") on the ...
![](https://cdn.snapi.dev/images/v1/t/j/conf2-2451358.jpg)
VolitionRx Limited to Present at Jefferies Global Healthcare Conference
HENDERSON, Nevada , May 29, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced today that Cameron Reynolds, President and Group...
![](https://cdn.snapi.dev/images/v1/l/x/press5-2428080.jpg)
VolitionRx Limited Announces First Quarter 2024 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for Tuesday, May 14 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.
![](https://cdn.snapi.dev/images/v1/b/l/conf12-2417797.jpg)
VolitionRx Limited Schedules First Quarter 2024 Earnings Conference Call and Business Update
Conference call to take place on Tuesday May 14 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.
![](https://cdn.snapi.dev/images/v1/d/1/press4-2385207.jpg)
Nu.Q® Vet Cancer Test launched in-clinic in U.S. and Europe through Antech
HENDERSON, Nev. , April 23, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has announced that its Nu.Q® Vet Cancer Test is now availa...
![](https://cdn.snapi.dev/images/v1/2/v/press13-2340681.jpg)
VolitionRx Limited Announces Full Fiscal Year 2023 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for Tuesday, March 26 at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.
![](https://cdn.snapi.dev/images/v1/e/h/conf8-2335144.jpg)
VolitionRx Limited Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call and Business Update
Conference call to take place on Tuesday March 26 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.
![](https://cdn.snapi.dev/images/v1/a/g/press9-2332987.jpg)
Volition and Fujifilm Vet Systems Launch Nu.Q® Vet Cancer Test in Japan
HENDERSON, Nev. , March 20, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has agreed a supply agreement with Fujifilm Vet Systems Co...
![](https://cdn.snapi.dev/images/v1/c/b/press15-2331914.jpg)
Volition appoints Dr Andrew Retter as Chief Medical Officer
HENDERSON, Nev. , March 19, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has appointed Dr Andrew Retter as its Chief Medical Office...
![](https://cdn.snapi.dev/images/v1/p/u/press10-2257527.jpg)
Volition to Share Nu.Q® NETs Strategy Update at Upcoming Webinar
HENDERSON, Nev. , Feb. 2, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE American: VNRX) ("Volition"), a multi-national epigenetics company, is taking part in a webinar hosted by Edison Group, to updat...
![](https://cdn.snapi.dev/images/v1/o/d/press12-2216264.jpg)
Volition Issues Business Review 2023
HENDERSON, Nev. , Jan. 4, 2024 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has issued a Business Review of 2023, outlining its key high...
![](https://cdn.snapi.dev/images/v1/b/p/press1-2183548.jpg)
VolitionRx Secures Approximately $5.5 Million in Belgium Regional Government Financing from Wallonie Entreprendre
HENDERSON, Nev. , Dec. 5, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has closed on an aggregate of Euro 5.0 million (approximatel...
![](https://cdn.snapi.dev/images/v1/z/m/press7-2158062.jpg)
VolitionRx Limited Announces Third Quarter 2023 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for Wednesday, November 15, at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.
![](https://cdn.snapi.dev/images/v1/v/r/conf12-2146664.jpg)
VolitionRx Limited Schedules Third Quarter 2023 Earnings Conference Call and Business Update
Conference call to take place on Wednesday November 15 at 8:30 a.m. U.S Eastern Time HENDERSON, Nev.
![](https://cdn.snapi.dev/images/v1/a/t/press10-2141046.jpg)
Volition and VPG Launch Nu.Q® Vet Cancer Test in UK & Ireland
HENDERSON, Nev. , Nov. 6, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, and Veterinary Pathology Group (VPG), a leading high quality...
![](https://cdn.snapi.dev/images/v1/q/y/press5-2115037.jpg)
Volition Presents Breakthrough Liquid Biopsy Blood Test Method for Early-stage Cancer
HENDERSON, Nev. , Oct. 23, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has unveiled what it believes to be an entirely new cancer ...
![](https://cdn.snapi.dev/images/v1/x/a/press15-2110860.jpg)
Measuring Nucleosomes Using Nu.Q® NETs is a Promising Biomarker for Septic Shock
HENDERSON, Nev. , Oct. 19, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces the publication of a clinical paper1 which shows ...
![](https://cdn.snapi.dev/images/v1/d/j/press9-2109363.jpg)
US Ambassador Adler visits Belgian Volition
HENDERSON, Nev. , Oct. 18, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, welcomed Ambassador Michael M.
![](https://cdn.snapi.dev/images/v1/a/7/press8-2104376.jpg)
Volition Presents Three Cancer Detection Abstracts at ESMO 2023
HENDERSON, Nev. , Oct. 16, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is presenting three scientific abstracts at ESMO 2023, the ...
![](https://cdn.snapi.dev/images/v1/y/r/press4-2102371.jpg)
Volition Publishes Key Opinion Leader Roundtable Report on NETs in Sepsis
HENDERSON, Nev. , Oct. 13, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, has published a report summarising key themes from its rece...
![](https://cdn.snapi.dev/images/v1/0/0/image21-2093042.jpeg)
Top 4 Health Care Stocks That Are Preparing To Pump This Quarter - Omega Therapeutics (NASDAQ:OMGA), Cutera (NASDAQ:CUTR)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
![](https://cdn.snapi.dev/images/v1/q/2/press15-2085604.jpg)
Volition to Reveal New Cancer Detection Method Insights at Upcoming Webinar
HENDERSON, Nev. , Oct. 2, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is taking part in a webinar hosted by Edison Group, to expou...
![](https://cdn.snapi.dev/images/v1/l/6/press15-2061312.jpg)
Volition Hosts Key Opinion Leader Roundtable on Sepsis Management
HENDERSON, Nev. , Sept. 13, 2023 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, is hosting a Key Opinion Leader ("KOL") roundtable discuss...
![](https://cdn.snapi.dev/images/v1/x/b/press13-2022447.jpg)
VolitionRx Limited Announces Second Quarter 2023 Financial Results and Business Update
Conference call to discuss financial and operational results scheduled for Tuesday, August 15, at 8:30 a.m. U.S. Eastern Time HENDERSON, Nev.